<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">J Am Pharm Assoc (2003)</journal-id><journal-id journal-id-type="iso-abbrev">J Am Pharm Assoc (2003)</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Journal of the American Pharmacists Association : JAPhA</journal-title></journal-title-group><issn pub-type="ppub">1544-3191</issn><issn pub-type="epub">1544-3450</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11059200</article-id><article-id pub-id-type="pmcid-ver">PMC11059200.1</article-id><article-id pub-id-type="pmcaid">11059200</article-id><article-id pub-id-type="pmcaiid">11059200</article-id><article-id pub-id-type="manuscript-id">NIHMS1983723</article-id><article-id pub-id-type="pmid">36653275</article-id><article-id pub-id-type="doi">10.1016/j.japh.2022.12.025</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1983723</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1983723</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Characteristics and health service use of Medicaid-insured individuals filling naloxone under a standing order in Louisiana</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Sugarman</surname><given-names initials="OK">Olivia K.</given-names></name><role>Postdoctoral Fellow</role><xref rid="CR1" ref-type="corresp">*</xref><aff id="A1">Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD; Program Manager, Louisiana State University Health Sciences Center - New Orleans, School of Medicine, Section of Community and Population Medicine, New Orleans, LA</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Breithaupt</surname><given-names initials="J">Jarrod</given-names></name><role>Health Data Analyst</role><aff id="A2">University of Louisiana, Monroe, College of Pharmacy, Office of Outcomes Research and Evaluation, Monroe, LA</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="X">Xiaojun</given-names></name><role>Senior Analyst</role><aff id="A3">University of Louisiana, Monroe, College of Pharmacy, Office of Outcomes Research and Evaluation, Monroe, LA</aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bachhuber</surname><given-names initials="MA">Marcus A.</given-names></name><role>Associate Professor of Clinical Medicine</role><aff id="A4">Louisiana State University Health Sciences Center - New Orleans, School of Medicine, Section of Community and Population Medicine, New Orleans, LA</aff></contrib></contrib-group><author-notes><corresp id="CR1"><label>*</label><bold>Correspondence:</bold> Olivia K. Sugarman, PhD, MPH, 624 N Broadway, 3rd floor. <email>okacsits@gmail.com</email> (O.K. Sugarman).</corresp><fn fn-type="COI-statement" id="FN1"><p id="P34"><bold>Disclosure:</bold> The authors declare no relevant conflicts of interest or financial relationships.</p></fn></author-notes><pub-date pub-type="ppub"><season>May-Jun</season><year>2023</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2022</year></pub-date><volume>63</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">461230</issue-id><fpage>904</fpage><lpage>908.e1</lpage><pub-history><event event-type="nihms-submitted"><date><day>15</day><month>04</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-15 19:25:12.460"><day>15</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1983723.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P1">Naloxone distribution is a key intervention to reduce opioid overdose deaths. On January 23, 2017, Louisiana implemented a standing order that permits pharmacies to dispense naloxone to patients without a patient-specific prescription.</p></sec><sec id="S2"><title>Objectives:</title><p id="P2">To examine the characteristics and health service use of Louisiana Medicaid members filling naloxone under the standing order.</p></sec><sec id="S3"><title>Methods:</title><p id="P3">We conducted a retrospective cohort study of Louisiana Medicaid members from January 23, 2017 to December 31, 2019. We extracted fee-for-service claims and managed care encounters for naloxone dispensed under the standing order.</p></sec><sec id="S4"><title>Results:</title><p id="P4">Overall, there were 2053 naloxone fills by 1912 unique individuals. The total number of naloxone fills increased from 22 in 2017 to 1218 in 2019. Most members (n = 1,586, 83.0%) received any type of health service and 20.4% (n = 391) received an opioid-related health service in the 30 days prior to filling naloxone. Additionally, 12.7% (n = 242) of members had received medication for opioid use disorder (MOUD), and 42.6% (n = 815) filled a prescription opioid analgesic within the 60 days prior to filling naloxone. Nineteen members (1.0%) had an emergency department visit for overdose within 90 days after filling naloxone.</p></sec><sec id="S5"><title>Conclusion:</title><p id="P5">Standing orders play an important role in providing access to naloxone, even among Medicaid members who had recent encounters with health care providers. We identified multiple opportunities to improve naloxone prescribing among providers caring for Medicaid-insured people who use opioids, including prescribers of opioid analgesics or MOUD.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>